stroke

Pharma

FDA approves Lilly's Mounjaro to reduce risk of cardio events

The FDA has signed off on a label expansion for Eli Lilly's Mounjaro to reduce the risk of heart attack or stroke in at-risk adults with type 2 diabetes.

Kevin Dunleavy Aug 28, 2026 10:52am

Merck bats for heart disease awareness

Apr 30, 2026 9:30am

UK cost watchdog clears Novo's Wegovy for cardio risk reduction

Apr 1, 2026 9:38am

heart stop delay heart stop stoplight red light

NIH stops Xarelto arm of stroke trial due to safety, efficacy

Feb 10, 2026 4:04pm

Pfizer confirms patient death in hemophilia drug trial

Dec 23, 2025 11:05am

Amgen's Repatha meets the mark in CV primary prevention trial

Oct 2, 2025 11:26am